Fintel reports that on December 8, 2025, Oppenheimer maintained coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

Capricor Therapeutics, Inc. soars 450% on positive HOPE-3 DMD results. Discover market impact, growth potential, and risks.

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...

The latest announcement is out from Capricor Therapeutics ( (CAPR) ).

Capricor jumps after Phase 3 data show Deramiocel improves heart function and slows muscle decline in Duchenne muscular ...

As of Monday, November 24, Capricor Therapeutics, Inc.’s CAPR share price has dipped by 9.03%, which has investors ...

In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...